Viking Therapeutics shares plunge on weight loss trial tolerability concerns

Viking Therapeutics (VKTX) shares plunged 43% following the release of Phase 2a Venture Oral trial data for its weight loss drug VK-2735, which showed strong efficacy with up to 11% placebo-adjusted weight loss but also significant tolerability concerns. Investor sentiment was impacted by higher dose-related vomiting (20-35%) and nausea (58%), alongside a 20% discontinuation rate, despite the company noting 99% of adverse events were mild or moderate. JPMorgan analysts, however, highlighted VK-2735's strong efficacy and a potentially manageable safety profile with an optimized titration approach.

Analysis

Viking Therapeutics (VKTX) experienced a 43% decline in its share price following the release of its Phase 2a Venture Oral trial data for the weight loss drug VK-2735. The market's reaction was driven by a clear dichotomy in the results: while the drug demonstrated strong dose-dependent efficacy, achieving up to 11% placebo-adjusted weight loss over 13 weeks, significant tolerability issues overshadowed this success. Investor sentiment soured on specific adverse event rates, including a 20% patient discontinuation rate versus 13% for placebo, vomiting in 20-35% of participants at higher doses, and nausea in 58% of participants. Although the company stated that 99% of these events were mild or moderate, the market heavily discounted the drug's prospects. In contrast to the sharp sell-off, analysts at JPMorgan provided a more nuanced perspective, describing the efficacy as strong and the safety profile as potentially manageable, particularly if an optimized dose titration strategy is implemented in future studies.

Key Decisions for Investors

• Investors should weigh the drug's strong efficacy against the significant commercial risk posed by its tolerability profile, particularly the high rates of nausea and discontinuation compared to placebo.
• The 43% share price collapse may present an opportunity for risk-tolerant investors who subscribe to JPMorgan's view that the side effects can be managed through a future optimized titration protocol.
• Monitor for any company guidance on dose titration strategies for subsequent trials, as this will be the key catalyst determining whether the drug's safety profile can be improved to a commercially competitive level.